| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Are toxicities of current nucleosides still a concern?
|
Vivancos, Maria J
|
|
2018
|
5 |
4 |
p. e156-e157
|
artikel
|
| 2 |
Commitment needed from South Africa's new president
|
The Lancet HIV,
|
|
2018
|
5 |
4 |
p. e155
|
artikel
|
| 3 |
Ending AIDS by 2030: catchy slogan or sincere goal?
|
Braithwaite, R Scott
|
|
2018
|
5 |
4 |
p. e160-e161
|
artikel
|
| 4 |
Indications for starting ART
|
Mussini, Cristina
|
|
2018
|
5 |
4 |
p. e157-e158
|
artikel
|
| 5 |
Migration and risk of HIV acquisition in Rakai, Uganda: a population-based cohort study
|
Olawore, Oluwasolape
|
|
2018
|
5 |
4 |
p. e181-e189
|
artikel
|
| 6 |
Migration patterns and HIV prevention in Uganda
|
Nöstlinger, Christiana
|
|
2018
|
5 |
4 |
p. e158-e160
|
artikel
|
| 7 |
Tenofovir alafenamide plus emtricitabine versus abacavir plus lamivudine for treatment of virologically suppressed HIV-1-infected adults: a randomised, double-blind, active-controlled, non-inferiority phase 3 trial
|
Winston, Alan
|
|
2018
|
5 |
4 |
p. e162-e171
|
artikel
|
| 8 |
The global Optima HIV allocative efficiency model: targeting resources in efforts to end AIDS
|
Kelly, Sherrie L
|
|
2018
|
5 |
4 |
p. e190-e198
|
artikel
|
| 9 |
Which HIV-infected adults with high CD4 T-cell counts benefit most from immediate initiation of antiretroviral therapy? A post-hoc subgroup analysis of the START trial
|
Molina, Jean-Michel
|
|
2018
|
5 |
4 |
p. e172-e180
|
artikel
|
Tijdschrift beschrijving